SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02387957

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

NCT02387957 Age-Related Macular Degeneration
MeSH:Macular Degeneration

4 Interventions

Name: Fovista®

Type: Drug
Group Labels: 3

Fovista® plus aflibercept Fovista® plus bevacizumab Fovista® plus ranibizumab

Name: bevacizumab

Type: Drug
Group Labels: 1

Fovista® plus bevacizumab

Name: ranibizumab

Type: Drug
Group Labels: 1

Fovista® plus ranibizumab

Name: aflibercept

Type: Drug
Group Labels: 1

Fovista® plus aflibercept


Primary Outcomes

Description: Number of Patients with Systemic Adverse Events

Measure: Total Numer of Systemic Adverse Events

Time: 2 years

Description: Number of Patients with Other Adverse Events

Measure: Total Number of Other Adverse Events (>5%)

Time: 2 years

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 Q12W

Subjects will be treated with "combination therapy" of IVT Fovista® and IVT anti-VEGF therapy every month for the first 5 months (Day 1, Months 1,2,3,4), followed by Q12W (every 12 weeks) administration (Months 7,10, 13,16, 19 and 22), for a total of 24 months. --- Q12W ---



HPO Nodes